Osnuvo

For the treatment of osteoporosis in patients at a high risk of fragility fractures who meet ALL the following criteria:

- 65 years of age or older; AND

- Has a documented bone mineral density [BMD] T-score of less than or equal to 3; AND

- Has a history of prior fragility fracture(s); AND

- Has used an anti-resorptive agent for osteoporosis which resulted in osteonecrosis of the jaw and/or an atypical femur fracture.

Note: The maximum lifetime exposure to teriparatide for an individual patient is 24 months